{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:03:39Z","timestamp":1791515019738,"version":"4.3.4"},"reference-count":54,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Bispecific T-cell engagers (TCEs) are revolutionizing patient care in multiple myeloma (MM). These monoclonal antibodies, that redirect T cells against cancer cells, are now approved for the treatment of triple-class exposed relapsed\/refractory MM (RRMM). They are currently tested in earlier lines of the disease, including in first line. Yet, primary resistance occurs in about one-third of patients with RRMM, and most responders eventually develop acquired resistance. Understanding the mechanisms of resistance to bispecific TCE is thus essential to improve immunotherapies in MM. Here, we review recent studies investigating the clinical and molecular determinants of resistance to bispecific TCE. Resistance can arise from tumor-intrinsic or tumor-extrinsic mechanisms. Tumor-intrinsic resistance involves various alterations leading to the loss of the target antigen, such as chromosome deletions, point mutations, or epigenetic silencing. Loss of major histocompatibility complex (MHC) class I, preventing MHC class I: T-cell receptor (TCR) costimulatory signaling, was also reported. Tumor-extrinsic resistance involves abundant exhausted T-cell clones and several factors generating an immunosuppressive microenvironment. Importantly, some resistance mechanisms impair response to 1 TCE while preserving the efficacy of others. We next discuss the clinical implications of these findings. Monitoring the status of target antigens in tumor cells and their immune environment will be key to select the most appropriate TCE for each patient and to design combination and sequencing strategies for immunotherapy in MM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012354","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:48:39Z","timestamp":1711046919000},"page":"2952-2959","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":54,"title":["Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-2839","authenticated-orcid":false,"given":"Eric","family":"Letouz\u00e9","sequence":"first","affiliation":[{"name":"1Nantes Universit\u00e9, INSERM, CNRS, Universit\u00e9 d'Angers, Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, Nantes, France"},{"name":"2University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"1Nantes Universit\u00e9, INSERM, CNRS, Universit\u00e9 d'Angers, Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, Nantes, France"},{"name":"3Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Munshi","sequence":"additional","affiliation":[{"name":"4Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"5Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Samur","sequence":"additional","affiliation":[{"name":"6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"7Veterans Affairs Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"1Nantes Universit\u00e9, INSERM, CNRS, Universit\u00e9 d'Angers, Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, Nantes, France"},{"name":"2University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"1Nantes Universit\u00e9, INSERM, CNRS, Universit\u00e9 d'Angers, Centre de Recherche en Canc\u00e9rologie et Immunologie Nantes Angers, Nantes, France"},{"name":"3Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"5","key":"2024061115205850300_bib1","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2024061115205850300_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024061115205850300_bib3","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024061115205850300_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2024061115205850300_bib5","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024061115205850300_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024061115205850300_bib7","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"10396","key":"2024061115205850300_bib8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"2024061115205850300_bib9","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"S3","key":"2024061115205850300_bib10","doi-asserted-by":"crossref","first-page":"e5955094","DOI":"10.1097\/01.HS9.0000967676.59550.94","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Touzeau","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"2024061115205850300_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from majesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024061115205850300_bib12","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell\u2013engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024061115205850300_bib13","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"2024061115205850300_bib14","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"13","key":"2024061115205850300_bib15","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 15","key":"2024061115205850300_bib16","article-title":"Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results","volume":"38","author":"Munshi","year":"2020","journal-title":"J\u00a0Clin Orthod"},{"issue":"8","key":"2024061115205850300_bib17","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"25","key":"2024061115205850300_bib18","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2024061115205850300_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"8","key":"2024061115205850300_bib20","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2024061115205850300_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"S2","key":"2024061115205850300_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/01.HS9.0000936256.84340.a7","article-title":"MajesTEC-1: correlative analyses of Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"van de Donk","year":"2023","journal-title":"Hemasphere"},{"key":"2024061115205850300_bib23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fonc.2020.00636","article-title":"Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities","volume":"10","author":"Leblay","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"2024061115205850300_bib24","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/HS9.0000000000000575","article-title":"Understanding the mechanisms of resistance to T cell-based immunotherapies to develop more favorable strategies in multiple myeloma","volume":"5","author":"Ahn","year":"2021","journal-title":"Hemasphere"},{"issue":"20","key":"2024061115205850300_bib25","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-12-3676","article-title":"Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance","volume":"19","author":"de Haart","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"2024061115205850300_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2019-125818","article-title":"The impact and modulation of microenvironment-induced immune resistance against CAR T cell and antibody treatments in multiple myeloma","volume":"134","author":"Holthof","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024061115205850300_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"7","key":"2024061115205850300_bib28","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","article-title":"Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow","volume":"190","author":"Ramachandran","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"15","key":"2024061115205850300_bib29","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","article-title":"Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans","volume":"121","author":"G\u00f6rg\u00fcn","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024061115205850300_bib30","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"2024061115205850300_bib31","article-title":"Genomic basis of multiple myeloma subtypes from the MMRF CoMMpass study","author":"Skerget","year":"5  2021","journal-title":"medRxiv"},{"issue":"21","key":"2024061115205850300_bib32","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.1182\/bloodadvances.2023010025","article-title":"Monoallelic deletion of BCMA is a frequent feature in multiple myeloma","volume":"7","author":"Samur","year":"2023","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2024061115205850300_bib33","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2023-182330","article-title":"Clinical outcomes of subsequent therapies in patients with relapsed\/refractory multiple myeloma following talquetamab treatment: analyses from the phase 1\/2 monumenTAL-1 study","volume":"142","author":"Sanchez","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"2024061115205850300_bib34","article-title":"Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"Suppl 1","key":"2024061115205850300_bib35","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1182\/blood-2023-190517","article-title":"Immune and genome profiling of myeloma patients treated with sequential immunotherapies reveal differential non-overlapping mechanisms of resistance","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024061115205850300_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"issue":"16","key":"2024061115205850300_bib37","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024061115205850300_bib38","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2024061115205850300_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"2024061115205850300_bib40","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"2024061115205850300_bib41","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"2024061115205850300_bib42","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure\u2013response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Targ Oncol"},{"issue":"Suppl 1","key":"2024061115205850300_bib43","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2023-190341","article-title":"Soluble B-cell maturation antigen as a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from elranatamab (ELRA) magnetismm studies","volume":"142","author":"Elmeliegy","year":"2023","journal-title":"Blood"},{"key":"2024061115205850300_bib44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"issue":"Suppl 1","key":"2024061115205850300_bib45","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1182\/blood-2023-188080","article-title":"The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024061115205850300_bib46","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-021-21445-4","article-title":"Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation","volume":"12","author":"Arenas","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"2024061115205850300_bib47","doi-asserted-by":"crossref","first-page":"111430","DOI":"10.1016\/j.celrep.2022.111430","article-title":"The target antigen determines the mechanism of acquired resistance to T cell-based therapies","volume":"41","author":"Mart\u00ednez-Sabadell","year":"2022","journal-title":"Cell Rep"},{"issue":"Suppl 16","key":"2024061115205850300_bib48","article-title":"First results from the RedirecTT-1 study with teclistamab (tec)\u00a0+ talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"17","key":"2024061115205850300_bib49","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2024061115205850300_bib50","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs augment CD3-bispecific antibody-induced CD8+ T-cell cytotoxicity and expansion by enhancing IL2 production","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"2024061115205850300_bib51","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab\u00a0+ pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b monumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"2024061115205850300_bib52","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.HS9.0000843644.02496.66","article-title":"S188: teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of replased\/refractory multiple myeloma: updated phase 1B results","volume":"6","author":"Rodriguez Otero","year":"2022","journal-title":"HemaSphere"},{"issue":"Suppl 16","key":"2024061115205850300_bib53","article-title":"Talquetamab (tal)\u00a0+ daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023","journal-title":"J\u00a0Clin Orthod"},{"issue":"S3","key":"2024061115205850300_bib54","doi-asserted-by":"crossref","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","article-title":"S194: reclistamab (TEC)\u00a0+ nirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): the 1B majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2952\/2228490\/blooda_adv-2023-012354-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2952\/2228490\/blooda_adv-2023-012354-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T17:00:56Z","timestamp":1718125256000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2952\/515381\/Mechanisms-of-resistance-to-bispecific-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012354","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]}}}